1645O Durvalumab (D) plus tremelimumab (T) for the treatment of patients with progressive, refractory advanced thyroid carcinoma: The DUTHY (GETNE-T1812) trial. - Capdevila Castillon, J.; Plana, M.; Castelo, B.; Iglesias, L.; Hernando, J.; Yaya Tur, R.; Baste, N.; Carmona-Bayonas, A.; Ruiz, S.; Trigo, J.; Lorenzo-Lorenzo, I.; Grande, E.; et al. (Annals of Oncology, 2022)